← Back to Search

Other

ATH-1017 for Alzheimer's Disease (ACT-AD Trial)

Phase 2
Waitlist Available
Research Sponsored by Athira Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline (day 1)
Awards & highlights

Summary

This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.

Eligible Conditions
  • Alzheimer's Disease
  • Alzheimer's Dementia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline (day 1)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline (day 1) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Event-related Potential (ERP) P300 Latency at Baseline
Secondary study objectives
Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) at Baseline

Side effects data

From 2022 Phase 2 trial • 77 Patients • NCT04491006
63%
Injection site reaction
22%
Eosinophilia
15%
Injection site vesicles
15%
Fatigue
15%
Headache
15%
Pruritus
11%
Injection site pain
11%
Paraesthesia
11%
Arthralgia
7%
Injection site erythema
7%
Dizziness
7%
Neutrophilia
7%
Fall
7%
Contusion
7%
Post procedural complication
7%
Lipohypertrophy
7%
Pollakiuria
4%
Skin exfoliation
4%
Rash pruritic
4%
Skin induration
4%
Vertigo
4%
Hip fracture
4%
Injection site induration
4%
Cholinergic syndrome
4%
Injection site paraesthesia
4%
Injection site pruritus
4%
Injection site mass
4%
Chest discomfort
4%
Pain
4%
Flushing
4%
Induration
4%
Immediate post-injection reaction
4%
Application site pruritus
4%
Feeling abnormal
4%
Extensor plantar response
4%
Dementia Alzheimer's type
4%
Syncope
4%
Parosmia
4%
Anaemia
4%
Thrombocytopenia
4%
Nausea
4%
Vomiting
4%
Diarrhoea
4%
Toothache
4%
Abdominal pain upper
4%
Wound secretion
4%
Skin abrasion
4%
Joint injury
4%
Pruritus allergic
4%
Hair colour changes
4%
Urticaria
4%
Back pain
4%
Agitation
4%
Disorientation
4%
Delirium
4%
Dysphemia
4%
Electrocardiogram QT prolonged
4%
Eosinophil count increased
4%
White blood cell count increased
4%
Upper respiratory tract infection
4%
Hyperlipidaemia
4%
Hypoglycaemia
4%
Hypotension
4%
Amaurosis fugax
4%
Genital paraesthesia
4%
Pneumonia aspiration
4%
Lung disorder
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
ATH-1017 40 mg
ATH-1017 70 mg

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low DoseExperimental Treatment1 Intervention
Daily subcutaneous (SC) injection of Low Dose ATH-1017
Group II: High DoseExperimental Treatment1 Intervention
Daily subcutaneous (SC) injection of High Dose ATH-1017
Group III: PlaceboPlacebo Group1 Intervention
Daily subcutaneous (SC) injection of Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATH-1017
2020
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Athira PharmaLead Sponsor
7 Previous Clinical Trials
1,244 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,704 Previous Clinical Trials
28,033,180 Total Patients Enrolled
~16 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top